Syngene purchases land to expand operations in Genome Valley, Hyderabad

§ The Ground-breaking ceremony was hosted by Kiran Mazumdar Shaw, Non-executive Chairperson, Syngene, and graced by K. T. Rama Rao, Hon’ble Minister of IT, Industries and Commerce, Telangana Government

§ Syngene plans to build state-of-the-art research laboratories and create up to 1000 jobs

Hyderabad, 14 September 2023: Syngene International Limited, a leading global contract research, development, and manufacturing services organization, announced the purchase of a 17-acre land parcel in Genome Valley, Hyderabad as an extension to its existing research campus. Construction of the new facilities will begin in 2024, following the necessary statutory approvals. The Company anticipates an investment of up to INR 788 crores to develop the expanded campus in Genome Valley to its full potential, including the creation of up to 1000 jobs in science, in the next 5 years.

The ground-breaking ceremony was graced by Honorable Minister Mr. K.T Rama Rao, Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications, Government of Telangana, Kiran Mazumdar Shaw, Chairperson, Syngene International Limited, Mr. Jayesh Ranjan, IAS, Principle Secretary, Industries and Commerce and IT, Government of Telangana, Mr. Venkata Narsimha Reddy, IAS, Vice Chairman & Managing Director – Telangana State Industrial Infrastructure Corporation (TSIIC), Mr. Shakthi Nagappan, Chief Executive Officer, Telangana Life Sciences, Mahesh Bhalgat, Chief Operating Officer, Syngene International and other senior leaders from Syngene.

Syngene’s existing research facility in Genome Valley was inaugurated in 2020 and accommodates over 900 scientists. The research carried out on the site focuses on discovery chemistry and biology, primarily for the global pharmaceutical industry. The site also includes a PROTAC laboratory that conducts leading edge research into disease-causing proteins, which lie at the heart of diseases such as cancer and a Central Compound Management facility which serves as a central storage facility for all compounds synthesized by Syngene scientists.

K. T. Rama Rao, Honourable Minister for Municipal Administration and Urban Development; Industries and Commerce; and Information Technology, Electronics and Communications, Government of Telangana expressed “Syngene’s expansion is a testament to the tremendous opportunities and support that our state provides. At Genome Valley, we aim to facilitate the necessary infrastructure and support systems to enable pioneering lifescience R&D activities. This expansion aligns with our vision to attract and nurture top talent, drive innovation and foster economic development.”

Kiran Mazumdar Shaw, Chairperson of Syngene International Ltd., said, “We are delighted to expand Syngene’s operations in Genome Valley with the addition of a large new research and development facility which will create additional jobs and contribute to the growth of the biotech industry. As a part of our commitment to drive innovation and strengthen the biotech ecosystem of the country, we will be investing up to INR 788 crores over the next few years, in Genome Valley in Hyderabad. I extend my congratulations to the Government of Telangana for their visionary efforts towards setting up a world class biotech hub in Hyderabad.”

Jonathan Hunt, Managing Director and Chief Executive Officer of Syngene International said, “Scientific innovation does not happen in isolation: it is a multi-dimensional process and we have been able to make all the connections that we need at Genome Valley. Syngene started operations in here in 2020 with the inauguration of our first research laboratory. Since then, we have gradually increased our presence encouraged by the good infrastructure and availability of scientific talent, which is ideal for fast-growing organizations like Syngene. In the last 3 years, our employee base has grown to over 900 scientists. In the next expansion phase, we plan to build world-class research laboratories primarily focusing on drug discovery that will create up to another 1000 jobs.”